Aberrantly methylated genes are promising biomarkers for the detection of colon adenomas and colorectal cancers (CRCs). The optimal assay type and specific methylated genes for these assays remain to be determined.
RESULTS: ITGA4 [integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor)] was identified as a novel gene frequently methylated in CRC. Methylated ITGA4 is present in 75% of colon adenomas (n ϭ 36) and 92% of colon adenocarcinomas (n ϭ 75). Comparison of end point MSP, end point MSP with clamped primers, and quantitative fluorescent MSP (qMSP) approaches revealed that both types of end point MSP assays could routinely detect as little as 70 pg DNA, whereas the qMSP assay could routinely detect as little as 7 pg. A fecal DNA qMSP assay for methylated ITGA4 can detect 69% of individuals with colon adenomas (n ϭ 13) with a diagnostic specificity of 79% (n ϭ 28).
CONCLUSIONS: Methylated ITGA4 is a promising marker gene for the early detection of colonic neoplasms. qMSP has the lowest limit of detection of the MSP assay types tested, and a qMSP assay that detects methylated ITGA4 has potential as an early-detection assay for colon neoplasms.
Mortality related to colorectal cancer (CRC) 8 can be reduced by screening with fecal occult blood tests and colonoscopy (1 ) . Neither of these screening modalities is optimal, however, because of low positive predictive values and low compliance, respectively. Thus, a substantial effort has been made to develop molecular marker assays that function as diagnostically accurate noninvasive markers for the early detection of colon adenomas and cancers and that have the potential to increase compliance. The use of stool-based DNA markers can potentially improve compliance, and such tests are more diagnostically specific than fecal occult blood tests (2, 3 ) ; however, the diagnostic sensitivity of the currently commercially available assay for detecting colon adenomas appears to be Ͻ50% (4, 5 ) . Some of this lack of diagnostic sensitivity appears to be related to the particular molecular markers assessed (6, 7 ) . Another reason for the suboptimal diagnostic sensitivity may be secondary to technical aspects related to the assay design (8 ) . Thus, we performed a genomewide screen for novel methylated genes that could be used as molecular markers for CRC and compared the performance characteristics of 3 different types of PCR-based assays for detecting these methylated genes.
For the studies described below, we used the VACO 235 and AA/C1 colorectal adenoma cell lines and the VACO 411, AA/C1/SB10, HT29, RKO, and SW48 CRC cell lines. The cell lines were grown as previously described (9, 10 ) . We used TRIzol (Invitrogen) to extract total RNA to be used in the microarray analysis and quantitative reverse-transcription PCR studies and carried out a second purification step with the RNeasy Kit (Qiagen). Extraction and purification were performed according to the manufacturers' protocols. We used both gene-unmasking methods and methods based on methylated CpG island amplification microarrays to identify genes that are aberrantly methyl-ated in colon neoplasms (11, 12 ) . Microarray data were analyzed with the aid of GenePix Pro (Molecular Devices), GDFilter (Fred Hutchinson Cancer Research Center), and GeneTraffic (Iobion Informatics); see File 1 in the Data Supplement that accompanies the online version of this Brief Communication at http://www. clinchem.org/content/vol55/issue8. These studies identified candidate methylated genes in the cell lines, including ITGA4 9 [integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor)], which we then assessed in more detail because we found this gene to be commonly methylated in primary colon neoplasms. Methylated ITGA4 was detected in adenoma cell lines AA/C1 and VACO 235 and in CRC cell lines AA/C1/SB10, VACO 411, HT29, RKO, and SW48 (see Fig. 1 in the online Data Supplement). To confirm methylation of the CpG island in the ITGA4 promoter, we performed bisulfite genomic sequencing of ITGA4 in cell lines AA/C1, VACO 235, AA/ C1/SB10, and VACO 411 (for methods see File 1 in the online Data Supplement). The CpG island of exon 1 was heavily methylated in all 4 tumor cell lines. The results of the methylation-specific PCR (MSP) assays for methylation status showed 100% correlation with the results for methylation status determined by bisulfite sequencing (see Fig. 2 in the online Data Supplement). Quantitative reverse-transcription PCR was performed as previously described, and the results revealed ITGA4 expression to be substantially increased after treatment of AAC1/SB10 with 5-aza-2Ј-deoxycytidine, a result consistent with methylation repressing the expression of ITGA4 (13 ) We then used MSP to assess the methylation status of ITGA4 in samples of colon mucosa (n ϭ 32) and colon neoplasms. Colorectal tumor samples (36 adenomas and 75 adenocarcinomas) were collected from patients treated at Vanderbilt University Medical Center, the VA Tennessee Valley Health Care System, Meharry Medical Center (Nashville, TN), and Samsung Medical Center (Seoul, Korea). Informed consent was obtained from the study individuals in accordance with protocols approved by the institutional review board of each institution (see Table 2 in the online Data Supplement for information on the cases). In addition, 32 colon mucosa samples from colons resected for benign disease were obtained from the Vanderbilt University Medical Center pathology archives. Clinical information for a subset of the cancer free cases has previously been reported. The mean age of the patients was 62 years (range, 35-80 years) (14 ) . DNA was extracted and analyzed by MSP as previously described (15 ) . Methylated ITGA4 was detected in 6% of the samples of colon mucosa (n ϭ 32), in 75% of adenomas (n ϭ 27), and in 92% of CRCs (n ϭ 69). Methylated ITGA4 was more common in cases of advanced adenoma than in early adenoma [87% (n ϭ 23) vs 54% (n ϭ 13); P ϭ 0.046, Fisher exact test].
We then evaluated the analytical performance characteristics of 3 different types of PCR-based assays to detect several methylated genes, including CDKN2A [cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4)], MGMT (O-6-methylguanine-DNA methyltransferase), MLH1 [mutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli)], and ITGA4. We compared end point MSP, end point MSP with clamped PCR primers, and quantitative fluorescent MSP (qMSP) to determine which assay type had the best limit of detection (16, 17 ) . We conducted this comparison with methylated and unmethylated DNA. For methylated DNA, we extracted genomic DNA from the CRC cell line SW48, which carries methylated CDKN2A, MGMT, MLH1, and ITGA4 and treated it with the CpG DNA methylase SssI (methylated DNA control). For unmethylated DNA, we used genomic DNA from peripheral blood leukocytes, which carry unmethylated CDKN2A, MGMT, MLH1, and ITGA4 genes (unmethylated DNA control). Initially, we performed a dilution experiment to determine the technical detection limits of the assay types. We analyzed serial dilutions of bisulfite-treated DNA from samples known to carry methylated CDKN2A, MGMT, MLH1, and ITGA4. The end point MSP assay with clamped primers had a 10-fold lower detection limit for methylated CDKN2A and a 2.5-fold lower detection limit for MLH1 and could detect as little as 7 pg of bisulfitetreated DNA. The detection limit of 7 pg DNA for methylated MGMT was unaffected by the use of the modified primer; however, the detection limit for methylated ITGA4 was 70 pg with either the unclamped or clamped primer (see Table 3 in the online Data Supplement). We then conducted an identical set of studies with qMSP assays to determine if this assay type would affect the technical sensitivity of the assay for methylated ITGA4. Application of the qMSP assay to the same serially diluted samples revealed a 10-fold improvement for detecting methylated ITGA4, with a minimal absolute DNA limit of detection of 7 pg (Fig. 1A) . Thus, the effect of the different assay methods appears to vary with the gene; the assay with the lowest detection limit for methylated ITGA4 appears to be qMSP.
We next tested the potential of the qMSP assay to detect methylated ITGA4 in samples of human fecal DNA. The fecal DNA samples from patients with histologically confirmed polyps (n ϭ 13) and patients with a polyp-free colon confirmed by colonoscopy (n ϭ 28) were obtained as previously described (14 ) . The sample-collection method is described in File 1 in the online Data Supplement. The mean r 2 value of the calibration curves performed in 7 experiments was 0.988 (CI, 0.98 -0.99; Fig. 1B) . Methylated ITGA4 was found in 69% (9 of 13) of the patients with colon adenomas and in 21% (6 of 28) of people with no polyps detected by colonoscopy (Table 1) . We also assessed the performance of the fecal DNA assay to detect polyps carrying methylated ITGA4, as detected by the end point MSP assay. We found that the fecal DNA-based end point MSP assay could detect 69% (13 informative cases) of the patients with polyps that carried methylated ITGA4 (see Table 4 in the online Data Supplement). The fecal DNA-based assay had a lower diagnostic sensitivity and specificity than the tissue-based results. We believe this finding reflects the facts that the fecal samples were collected without the use of a stabilization buffer and capture probes were not used to enrich for methylated ITGA4, which are technical limitations that will be addressed in future studies. Of note is that we did not normalize the samples for input DNA because the majority of the DNA present in the samples is from the nonpathologic colon epithelium and therefore not relevant for assessing the tumor-specific DNA present in the sample. Assessment of the amount of unmethylated Alu DNA in the sample (which is an indicator of the total amount of input DNA) did permit an evaluation of the quality and overall amount of DNA in the samples (see File 1 in the online Data Supplement for details on the assay used to measure Alu DNA).
In summary, methylated ITGA4 is a potential fecal DNA-based early-detection marker for CRC. The qMSP assay had the lowest limit of detection for methylated ITGA4. The ITGA4 qMSP assay that we have designed can detect 1 genome equivalent of tumor DNA and has a 73% diagnostic sensitivity for patients with colon adenomas when the assay is used on fecal DNA. It is important to note that, in general, end point MSP is the most diagnostically sensitive assay type; however, qMSP is usually desirable because optimal thresholds can be determined to maximize the performance of the assay for specific clinical applications. Further assessment of methylated ITGA4 as an earlydetection marker and development of additional qMSP-based assays for other genes methylated in CRC are warranted.
